Palisade Bio Shares Insights on PDE4B for Patient Stratification
Recent research has emphasized the presence of PDE4B in different patient groups, indicating its potential as a significant marker for stratifying individuals with ulcerative colitis (UC). Notably, around 70% of adult colitis patients and 90% of pediatric patients showed PDE4B levels exceeding a specific threshold.
Progress with PALI-2108
Palisade Bio is committed to the development of PALI-2108, an innovative orally administered prodrug specifically targeting the colon. This localized PDE4 inhibitor is currently being assessed for its effectiveness against UC. The company is preparing to launch a Phase 1 clinical trial for PALI-2108, reinforcing its dedication to improving treatment options for patients dealing with this chronic illness.
Collaboration with Strand Life Sciences
In collaboration with Strand Life Sciences, Palisade Bio has enhanced its patient selection strategies based on PDE4-related biomarkers. This initiative aims to improve therapy outcomes for patients with UC. An analysis of RNA sequencing (RNAseq) data, conducted through a comprehensive bioinformatics framework, revealed a significant increase in PDE4B expression in both adult and pediatric groups, highlighting its potential to address varying patient needs.
Implications of PDE4B Expression
The analysis showed that patients experiencing moderate to severe UC typically have elevated PDE4B expression, with 70% of adult patients and 90% of children meeting the established criteria. Dr. Mitch Jones, Chief Medical Officer at Palisade Bio, emphasized the importance of these findings, suggesting that PDE4B could play a crucial role in guiding personalized treatment strategies, ultimately enhancing care delivery.
Promising Preclinical Results
A recent preclinical study utilizing a mouse model for DSS-induced colitis revealed significant increases in PDE4B levels following DSS treatment. Researchers found a direct link between heightened PDE4B levels and inflammation, which was alleviated with PALI-2108 administration. The study demonstrated a reduction in disease activity index scores, along with improvements in body weight and colon length metrics in treated groups, underscoring the drug's potential effectiveness.
About Palisade Bio
Palisade Bio is a biopharmaceutical company dedicated to discovering and advancing innovative therapies for autoimmune, inflammatory, and fibrotic diseases. With a focus on targeted solutions, Palisade aims to transform treatment paradigms for patients in need, solidifying its role in the industry.
Frequently Asked Questions
What is PDE4B and why is it important?
PDE4B is an enzyme that plays a vital role in managing inflammation. Its expression levels can help identify patients who may benefit from targeted treatments for conditions like ulcerative colitis.
What is PALI-2108?
PALI-2108 is an orally administered prodrug that inhibits PDE4, specifically designed to act in the colon, aimed at treating ulcerative colitis.
How effective is PALI-2108 based on current studies?
Preliminary studies suggest that PALI-2108 shows promising potential in reducing inflammation and enhancing clinical outcomes in preclinical models.
Who can benefit from the findings of this research?
The research findings may benefit patients suffering from moderate to severe ulcerative colitis by offering a more personalized treatment approach based on PDE4B expression levels.
Where can I find more information about Palisade Bio?
Additional information about Palisade Bio and its ongoing clinical programs can be found on their official website.
